Payment overview · 2025
General Payments
$30,457.86
173 reported records · 19 companies
Healthcare provider profile · identity verified
Azmi Draw, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · PROSPECT, KY · NPI 1801878806
Verified facts
What the public records show
CMS Open Payments records show Azmi Draw, MD received $30,457.86 in general payments during 2025 across 173 reported records.
AstraZeneca Pharmaceuticals LP accounted for 70.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Arikayce, Glassia, Nucala, Ofev, Trelegy Ellipta.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 997 claims for Trelegy Ellipta by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arikayce by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21,498.19 | 70.6% | 44 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $6,982.97 | 22.9% | 26 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $419.22 | 1.4% | 27 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $281.84 | 0.9% | 11 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $256.26 | 0.8% | 16 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $199.73 | 0.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $169.81 | 0.6% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.64 | 0.4% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $96.67 | 0.3% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $89.99 | 0.3% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $83.14 | 0.3% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $79.20 | 0.3% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $45.93 | 0.1% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $40.84 | 0.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.98 | 0.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $21.35 | 0.1% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $17.37 | 0.1% | 1 | 2025 |
| Liquidia Technologies, Inc. | Unresolved — no canonical attribution shown | $13.86 | 0.1% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $12.87 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,070.00 | 11 |
| Honoraria | $6,000.00 | 3 |
| Food and Beverage | $3,742.07 | 154 |
| Education | $645.79 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21,257.29 | 30 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $6,982.97 | 26 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $386.39 | 13 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $275.04 | 19 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $256.26 | 16 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $234.66 | 13 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $204.85 | 10 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $169.77 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $144.18 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.39 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $83.78 | 5 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $83.14 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $79.20 | 4 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $45.93 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $39.07 | 3 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $21.35 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| YUTREPIA Normalized: yutrepia |
Drug | Liquidia Technologies, Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $12.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Arikayce arikayce |
2025 | Arikayce | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GLASSIA glassia |
2025 | Glassia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 145 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 997 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
183 | 54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
145 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
997 | 189 |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Theophylline Er | Theophylline Anhydrous | 1402 | 280 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 997 | 189 |
| Montelukast Sodium | Montelukast Sodium | 988 | 223 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 862 | 290 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 720 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 81 |
| Prednisone | Prednisone | 370 | 168 |
| Eliquis | Apixaban | 365 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 340 | 61 |
| Furosemide | Furosemide | 308 | 71 |
| Azithromycin | Azithromycin | 284 | 152 |
| Omeprazole | Omeprazole | 282 | 64 |
| Roflumilast | Roflumilast | 259 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 42 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 226 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 40 |
| Spiriva Respimat | Tiotropium Bromide | 209 | 40 |
| Lisinopril | Lisinopril | 202 | 32 |
| Potassium Chloride | Potassium Chloride | 200 | 43 |
| Temazepam | Temazepam | 194 | 24 |
| Gabapentin | Gabapentin | 188 | 35 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 184 | 49 |
| Donepezil Hcl | Donepezil Hcl | 184 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 183 | 54 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 175 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 31 |
| Sertraline Hcl | Sertraline Hcl | 160 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 25 |
| Ofev | Nintedanib Esylate | 145 | 20 |
| Carvedilol | Carvedilol | 143 | 23 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 142 | 29 |
| Memantine Hcl | Memantine Hcl | 138 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 40 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 132 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 129 | 24 |
| Losartan Potassium | Losartan Potassium | 125 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 122 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 23 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 120 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 30 |
| Trazodone Hcl | Trazodone Hcl | 117 | 28 |
| Famotidine | Famotidine | 116 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 25 |
| Rifampin | Rifampin | 116 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 102 | 24 |
| Metformin Hcl | Metformin Hcl | 96 | 17 |
| Breyna | Budesonide/Formoterol Fumarate | 95 | 29 |
| Clonazepam | Clonazepam | 95 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 13 |
| Allopurinol | Allopurinol | 93 | 13 |
| Ethambutol Hcl | Ethambutol Hcl | 92 | 28 |
| Ondansetron Odt | Ondansetron | 88 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 61 |
| Atenolol | Atenolol | 83 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 81 | 22 |
| Hydrocortisone | Hydrocortisone | 80 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 11 |
| Divalproex Sodium | Divalproex Sodium | 73 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 66 | 24 |
| Spironolactone | Spironolactone | 62 | 19 |
| Levetiracetam | Levetiracetam | 54 | 13 |
| Modafinil | Modafinil | 54 | suppressed |
| Nystatin | Nystatin | 53 | 25 |
| Bumetanide | Bumetanide | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 44 | 14 |
| Baclofen | Baclofen | 43 | suppressed |
| Budesonide | Budesonide | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Brilinta | Ticagrelor | 40 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 16 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 21 |
| Digoxin | Digoxin | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 16 |
| Zaleplon | Zaleplon | 30 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 29 | 16 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Admelog Solostar | Insulin Lispro | 28 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 23 |
| Levofloxacin | Levofloxacin | 27 | 20 |
| Risperidone | Risperidone | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 25 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Restasis | Cyclosporine | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Nucala | Mepolizumab | 24 | suppressed |
| Sirolimus | Sirolimus | 24 | suppressed |
| Xolair | Omalizumab | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Daliresp | Roflumilast | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Fasenra Pen | Benralizumab | 14 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dupixent Syringe | Dupilumab | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Opsumit | Macitentan | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,457.86 · 173 records | AstraZeneca Pharmaceuticals LP | ACTHAR, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, DUPIXENT, FASENRA, GLASSIA, JASCAYD, LUNA, NUCALA, OFEV, Ohtuvayre, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, WAKIX, YUPELRI, YUTREPIA, Zemaira | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error